Biopharmaceutical company, Telix
(ASX:TLX) has secured ethics approval to commence a Phase1/11 study for the use of its drug to treat recurrent glioblastoma.
The approval pertains to the lead clinical sites of Kepler University and University Hospital Vienna.
The study is an international multi-centre, open-label dose ranging study.
Telix says it’s a unique study that combines the benefits of external-beam radiation with molecularly charged radiation.
Shares in Telix
(ASX:TLX) are trading is trading 2.43 per cent higher to 95 cents.
